Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
about
Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot studyRenal replacement therapy in acute kidney injury: controversy and consensusArgatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis.Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
P2860
Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Use of a low-molecular-weight ...... py in intensive care patients.
@ast
Use of a low-molecular-weight ...... py in intensive care patients.
@en
Use of a low-molecular-weight heparinoid
@nl
type
label
Use of a low-molecular-weight ...... py in intensive care patients.
@ast
Use of a low-molecular-weight ...... py in intensive care patients.
@en
Use of a low-molecular-weight heparinoid
@nl
prefLabel
Use of a low-molecular-weight ...... py in intensive care patients.
@ast
Use of a low-molecular-weight ...... py in intensive care patients.
@en
Use of a low-molecular-weight heparinoid
@nl
P2093
P2860
P1476
Use of a low-molecular-weight ...... py in intensive care patients.
@en
P2093
E Lindhoff-Last
R Bauersachs
P2860
P304
P356
10.1177/107602960100700409
P577
2001-10-01T00:00:00Z